Wen Wee Ma MBBS

Wen Wee Ma, M.B.B.S., conducts clinical and translational research in developing anti-cancer agents in the clinic and laboratory for patients with refractory solid tumors and gastrointestinal cancers.

Dr. Ma collaborates extensively with scientists and biotech partners in designing and executing first-in-human clinical trials and clinical studies with translational endpoints. His research has led to the launch of phase II and III clinical trials and contributed to the regulatory approval of nab-paclitaxel for treating pancreatic cancer and uridine triacetate for severe chemotherapy toxicity.